For atrial fibrillation ablation, newer anticoagulant reduces major bleeds

(American College of Cardiology) Uninterrupted treatment with dabigatran, a non-vitamin K antagonist oral anticoagulant (NOACs), before, during and after ablation to treat atrial fibrillation significantly reduced the incidence of major bleeding events compared with uninterrupted use of the more established anticoagulant warfarin, according to research presented at the American College of Cardiology's 66th Annual Scientific Session.